2006 Fiscal Year Final Research Report Summary
Ordermade treatment using analysis of EGFR gene abnormality in non-small cell lung cancer
| Project/Area Number |
17390385
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | NAGOYA CITY UNIVERSITY |
|---|
Principal Investigator |
FUJII Yoshitaka Nagoya City University, Graduate School of Medical Sciences, Professor and Chair, 大学院医学研究科, 教授 (40156831)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YANO Motoki Nagoya City University, Graduate School of Medical Sciences, Assistant Professor, 大学院医学研究科, 講師 (40315883)
SASAKI Hidefumi Nagoya City University, Graduate School of Medical Sciences, Research Associate, 大学院医学研究科, 助手 (00336695)
HANEDA Hiroshi Nagoya City University, Graduate School of Medical Sciences, Rinshoukenkyuui, 大学院医学研究科, 臨床研究医 (50381893)
ENDO Katsuhiko Nagoya City University, Graduate School of Medical Sciences, Rinsyoukenkyuui, 大学院医学研究科, 臨床研究医 (10381873)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Keywords | lung cancer / gene / made-to-order |
|---|
| Research Abstract |
1. Using probes for the 13 different mutations including 11 that have already been reported, we have genotyped the EGFR mutation status in 400 non small cell lung cancer patients operated between 2000-2006 at Nagoya City
University Hospital using the TaqMan PCR assay.
We have evaluated the relationships among the EGFR mutation, clinical-pathologic factors, gefitinib sensitivity, and overall survival.
We show in our previous paper that the TaqMan PCR assay is sensitive enough to detect the mutation in samples contaminated with 9 fold excess of wild type samples.
Therefore, we have analyzed small samples obtained from CT guided biopsy or trans-bronchial biopsy.
2. Some studies reported that downstream signaling molecules, EGFR gene amplification, and the expression of the other ErbB receptors were the other predictors of gefitinib sensitivity. Therefore, we have analyzed the other biomarkers, as the EGFR copy number, the ErbB2 copy number and PIK3CA gene mutation and have evaluated the relationship between their biomarkers and clinical-pathologic factors.
3. We have reported these studies at the annual meetings and have published them as an article.
4. In the future, we hope that EGFR mutation status using TaqMan PCR assay contributes to made-to-order treatment
|
